Mark Purcell
Stock Analyst at Morgan Stanley
(1.54)
# 3,678
Out of 5,182 analysts
7
Total ratings
75%
Success rate
-4.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Maintains: Overweight | $143 → $170 | $154.03 | +10.37% | 2 | Mar 26, 2026 | |
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $47.89 | +21.11% | 2 | Sep 8, 2025 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $56.69 | -22.38% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $203.49 | -58.23% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $36.98 | +224.50% | 1 | Jan 23, 2024 |
Novartis AG
Mar 26, 2026
Maintains: Overweight
Price Target: $143 → $170
Current: $154.03
Upside: +10.37%
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $47.89
Upside: +21.11%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $56.69
Upside: -22.38%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $203.49
Upside: -58.23%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $36.98
Upside: +224.50%